ArticleBiological trace element research2025
Elevated Serum Magnesium Levels May Delay the Loss of Residual Renal Function among Patients Receiving Peritoneal Dialysis: A Prospective Study.
Article in Biological trace element research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between serum magnesium and residual renal function (RRF) among peritoneal dialysis (PD) patients remains unclear. The present study examined the relationships between serum magnesium and the risk of anuria in patients receiving continuous ambulatory peritoneal dialysis (CAPD). This prospective cohort study included 261 PD patients in China. All participants received CAPD for more than 3 months between 2012 and December 2022. Loss of RRF (anuria) was characterized by a 24-h urine output below 100 ml. Cox proportional hazard regression models and competing risk models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of anuria across different serum magnesium levels. During the median follow-up of 21.3 (15.0-32.4) months, 130 individuals progressed to anuria. The mean concentration of serum magnesium was 0.9 ± 0.15 mmol/L. After multivariate adjustment, the association of serum magnesium with the risk of anuria was not significant in the entire study population. However, for PD patients with better preservation of RRF, the risk of anuria decreases significantly as serum magnesium increases (HR for per standard deviation increment 0.53, 95% CI 0.32-0.88). The protective effect of increased serum magnesium concentrations on RRF was more pronounced among PD patients with lower triglyceride glucose (TyG) index at baseline compared to those with higher TyG index (p for interaction = 0.03). Our results indicated that higher serum magnesium predicts better renal prognosis for PD patients with better preservation of RRF. Levels of TyG index may modulate the relationship.
Indexed as
Identifiers
39477852What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.